FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059617293> ?p ?o ?g. }

• W2059617293 endingPage "33351" @default.
• W2059617293 startingPage "33343" @default.
• W2059617293 abstract "DYRK1A is a serine/threonine kinase that has been linked to mental retardation associated with Down syndrome. In the present report, we describe a previously unknown role for DYRK1A in bone homeostasis. The protein expression of DYRK1A increased during osteoclast differentiation. In vitro studies in osteoclasts revealed that DYRK1A inhibited osteoclastogenesis. Whereas DYRK1A phosphorylated and inhibited the osteoclastogenic transcription factor NFATc1, forced expression of NFATc1 induced DYRK1A expression, suggesting a negative feedback loop. Transgenic mice overexpressing DYRK1A by the extent of the increased gene dosage in Down syndrome exhibited significantly reduced bone mass despite the decreased osteoclastogenesis, which is reminiscent of osteoporotic bone phenotype in Down syndrome patients. In these mice, attenuated osteoblast differentiation and function in the presence of extra DYRK1A overrode the effect of impaired osteoclastogenesis. However, impeded osteoclastogenesis in DYRK1A transgenic mice was proven to be beneficial in protecting bone loss induced by inflammation or estrogen deficiency. These results provide novel insight into the role for DYRK1A in bone homeostasis as well as in bone destructive diseases, in which modulation of DYRK1A might be used as a strategy to treat unregulated bone resorption. DYRK1A is a serine/threonine kinase that has been linked to mental retardation associated with Down syndrome. In the present report, we describe a previously unknown role for DYRK1A in bone homeostasis. The protein expression of DYRK1A increased during osteoclast differentiation. In vitro studies in osteoclasts revealed that DYRK1A inhibited osteoclastogenesis. Whereas DYRK1A phosphorylated and inhibited the osteoclastogenic transcription factor NFATc1, forced expression of NFATc1 induced DYRK1A expression, suggesting a negative feedback loop. Transgenic mice overexpressing DYRK1A by the extent of the increased gene dosage in Down syndrome exhibited significantly reduced bone mass despite the decreased osteoclastogenesis, which is reminiscent of osteoporotic bone phenotype in Down syndrome patients. In these mice, attenuated osteoblast differentiation and function in the presence of extra DYRK1A overrode the effect of impaired osteoclastogenesis. However, impeded osteoclastogenesis in DYRK1A transgenic mice was proven to be beneficial in protecting bone loss induced by inflammation or estrogen deficiency. These results provide novel insight into the role for DYRK1A in bone homeostasis as well as in bone destructive diseases, in which modulation of DYRK1A might be used as a strategy to treat unregulated bone resorption. DYRK1A (dual specificity tyrosine-regulated kinase 1A) is a member of genetically conserved protein kinases that phosphorylate serine/threonine residues on substrates and autophosphorylate on tyrosine residues (1.Becker W. Joost H.G. Prog. Nucleic Acids Res. Mol. Biol. 1999; 62: 1-17Crossref PubMed Scopus (189) Google Scholar, 2.Kentrup H. Becker W. Heukelbach J. Wilmes A. Schürmann A. Huppertz C. Kainulainen H. Joost H.G. J. Biol. Chem. 1996; 271: 3488-3495Abstract Full Text Full Text PDF PubMed Scopus (210) Google Scholar). Most evidence has so far indicated that DYRK1A is mainly linked to brain development (3.Fotaki V. Dierssen M. Alcántara S. Martínez S. Martí E. Casas C. Visa J. Soriano E. Estivill X. Arbonés M.L. Mol. Cell Biol. 2002; 22: 6636-6647Crossref PubMed Scopus (252) Google Scholar) and mental retardation associated with Down syndrome (4.Smith D.J. Stevens M.E. Sudanagunta S.P. Bronson R.T. Makhinson M. Watabe A.M. O'Dell T.J. Fung J. Weier H.U. Cheng J.F. Rubin E.M. Nat. Genet. 1997; 16: 28-36Crossref PubMed Scopus (265) Google Scholar, 5.Altafaj X. Dierssen M. Baamonde C. Martí E. Visa J. Guimerà J. Oset M. González J.R. Flórez J. Fillat C. Estivill X. Hum. Mol. Genet. 2001; 10: 1915-1923Crossref PubMed Scopus (327) Google Scholar, 6.Ahn K.J. Jeong H.K. Choi H.S. Ryoo S.R. Kim Y.J. Goo J.S. Choi S.Y. Han J.S. Ha I. Song W.J. Neurobiol. Dis. 2006; 22: 463-472Crossref PubMed Scopus (172) Google Scholar). However, the broad tissue distribution of DYRK1A (7.Becker W. Weber Y. Wetzel K. Eirmbter K. Tejedor F.J. Joost H.G. J. Biol. Chem. 1998; 273: 25893-25902Abstract Full Text Full Text PDF PubMed Scopus (241) Google Scholar) suggests a possibility of hitherto unknown functions in addition to its role in neurodevelopment. In the presence of macrophage colony-stimulating factor (M-CSF) 3The abbreviations used are: M-CSFmacrophage colony-stimulating factorRANKLreceptor activator of nuclear factor κB ligandBMMbone marrow macrophageTRAPtartrate-resistant acid phosphataseTGtransgenicWTwild typeLPSlipopolysaccharidePBSphosphate-buffered salineAbantibodyCAconstitutively activemicroCTmicrocomputed tomographyBVbone volumeTVtissue volume. and receptor activator of nuclear factor κB ligand (RANKL), macrophage/monocyte lineage of hematopoietic precursor cells differentiate into osteoclasts, cells specialized for bone resorption (8.Teitelbaum S.L. Science. 2000; 289: 1504-1508Crossref PubMed Scopus (3075) Google Scholar, 9.Boyle W.J. Simonet W.S. Lacey D.L. Nature. 2003; 423: 337-342Crossref PubMed Scopus (4916) Google Scholar, 10.Arai F. Miyamoto T. Ohneda O. Inada T. Sudo T. Brasel K. Miyata T. Anderson D.M. Suda T. J. Exp. Med. 1999; 190: 1741-1754Crossref PubMed Scopus (555) Google Scholar). M-CSF supports survival and proliferation of osteoclast precursors as well as expression of RANKL receptor (RANK). RANKL induces signaling cascades, including the recruitment of TNF receptor-associated factors, activation of mitogen-activated kinases, stimulation of NFκB and c-Fos transcription factors, and phospholipase Cγ-dependent calcium signaling, all of which culminate in the induction and activation of NFATc1, a “master” transcription factor for osteoclastogenesis (11.Asagiri M. Takayanagi H. Bone. 2007; 40: 251-264Crossref PubMed Scopus (1047) Google Scholar, 12.Lee Z.H. Kim H.H. Biochem. Biophys. Res. Commun. 2003; 305: 211-214Crossref PubMed Scopus (327) Google Scholar, 13.Theill L.E. Boyle W.J. Penninger J.M. Annu. Rev. Immunol. 2002; 20: 795-823Crossref PubMed Scopus (673) Google Scholar, 14.Wada T. Nakashima T. Hiroshi N. Penninger J.M. Trends Mol. Med. 2006; 12: 17-25Abstract Full Text Full Text PDF PubMed Scopus (878) Google Scholar). macrophage colony-stimulating factor receptor activator of nuclear factor κB ligand bone marrow macrophage tartrate-resistant acid phosphatase transgenic wild type lipopolysaccharide phosphate-buffered saline antibody constitutively active microcomputed tomography bone volume tissue volume. Through a proteomic approach, we discovered that the expression of DYRK1 family protein was significantly up-regulated during osteoclastogenesis. Recent studies of Drosophila RNA interference screening and examination of genes in the Down syndrome critical region reported that DYRK1A facilitates nuclear export of NFAT (15.Gwack Y. Sharma S. Nardone J. Tanasa B. Iuga A. Srikanth S. Okamura H. Bolton D. Feske S. Hogan P.G. Rao A. Nature. 2006; 441: 646-650Crossref PubMed Scopus (317) Google Scholar, 16.Arron J.R. Winslow M.M. Polleri A. Chang C.P. Wu H. Gao X. Neilson J.R. Chen L. Heit J.J. Kim S.K. Yamasaki N. Miyakawa T. Francke U. Graef I.A. Crabtree G.R. Nature. 2006; 441: 595-600Crossref PubMed Scopus (549) Google Scholar). Here we show that DYRK1A functions as a negative feedback regulator of NFATc1 in the modulation of bone homeostasis in vivo. Our results indicate a novel function of DYRK1A for bone cell regulation that might be applied to the treatment of bone-destructive diseases. Five-week-old ICR mice were obtained from Charles River Laboratories (Wilmington, MA). DYRK1A TG mice expressing human DYRK1A and WT littermates of C57BL/6 background were described previously (6.Ahn K.J. Jeong H.K. Choi H.S. Ryoo S.R. Kim Y.J. Goo J.S. Choi S.Y. Han J.S. Ha I. Song W.J. Neurobiol. Dis. 2006; 22: 463-472Crossref PubMed Scopus (172) Google Scholar). For the LPS-induced bone loss model, male WT or DYRK1A TG mice (6 weeks old) were injected intraperitoneally with PBS or LPS (Sigma; O111:B4; 5 mg/kg) dissolved in PBS of 200-μl volume at 7 and 3 days before sacrifice. For the ovariectomy-induced bone loss model, female WT and DYRK1A TG mice (14 weeks old) were either ovariectomized or sham-operated at 4 weeks before sacrifice. Animal experimental protocols were approved by the committees on the care and use of animals in research at Seoul National University and Inje University. Recombinant human soluble RANKL, human M-CSF, and human BMP-2 were purchased from PeproTech (Rocky Hill, NJ). The leukocyte acid phosphatase assay kit was from Sigma. Lipofectamine 2000TM was from Invitrogen. Antibodies (Abs) against DYRK1A (M01) and DYRK1B were from Abnova (Taipei, Taiwan) and Abgent (San Diego, CA), respectively. Abs against NFATc1 (7A6), Lamin B (M-20), and c-Fos (H-125) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The 7A6 anti-NFATc1 Ab was raised against a fragment of human NFATc1 that is conserved in all six known mouse isoforms. Anti-β-actin (AC-74) was from Sigma. Phosphospecific Abs for ERK (Thr202/Tyr204), JNK (Thr182/Tyr185), and p38 (Thr180/Tyr182) were from Cell Signaling Technology (Beverly, MA). Anti-phosphoserine Ab (3C171) was from Abcam (Cambridge, UK). Ionomycin and cyclosporin A were obtained from Calbiochem. All other chemicals were purchased from Sigma. Immunoprecipitates, whole cell lysates, or nuclear extracts from the same number of cells were subjected to 10% SDS-PAGE followed by immunodetection using chemiluminescence (17.Lee Y. Hyung S.W. Jung H.J. Kim H.J. Staerk J. Constantinescu S.N. Chang E.J. Lee Z.H. Lee S.W. Kim H.H. Blood. 2008; 111: 885-893Crossref PubMed Scopus (36) Google Scholar). The mRNA expression of genes was quantified by the methods described previously (17.Lee Y. Hyung S.W. Jung H.J. Kim H.J. Staerk J. Constantinescu S.N. Chang E.J. Lee Z.H. Lee S.W. Kim H.H. Blood. 2008; 111: 885-893Crossref PubMed Scopus (36) Google Scholar). Primer sequences for real-time PCR analyses were listed in supplemental Table S1. BMMs (2 × 104 cells/well in 48-well plastic plates) were incubated with 30 ng/ml M-CSF and 100 ng/ml RANKL for 3–4 days. At the end of incubation, osteoclast differentiation was determined by staining for TRAP activity using a leukocyte acid phosphatase assay kit (Sigma), and cells were photographed as previously described (17.Lee Y. Hyung S.W. Jung H.J. Kim H.J. Staerk J. Constantinescu S.N. Chang E.J. Lee Z.H. Lee S.W. Kim H.H. Blood. 2008; 111: 885-893Crossref PubMed Scopus (36) Google Scholar). In some experiments, BMMs were cocultured with osteoblasts (104/well) in the presence of 10 nm 1α,25-dihydroxyvitamin D3 and 1 μm prostaglandin E2. Calvarial cells were prepared from 1-day-old mice (18.Ryu J. Kim H.J. Chang E.J. Huang H. Banno Y. Kim H.H. EMBO J. 2006; 25: 5840-5851Crossref PubMed Scopus (229) Google Scholar). Osteoblast differentiation was induced by treating cells (104/well in 48-well plates) with either 10 mm β-glycerophosphate plus 100 μm ascorbic acid or 300 ng/ml BMP-2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. After 6 days, cells were stained for alkaline phosphatase activity. The intensity of alkaline phosphatase staining was quantified by scanning of cell culture plates (PowerLook 1100 scanner) followed by measuring the integrated density using the ImageJ program (version 1.40; available on the National Institutes of Health web site). Alternatively, the mineralization was visualized by alizarin red staining after 2–3 weeks of culture. pcDNA3.1-DYRK1A was prepared from mouse brain cDNA (19.Ryoo S.R. Jeong H.K. Radnaabazar C. Yoo J.J. Cho H.J. Lee H.W. Kim I.S. Cheon Y.H. Ahn Y.S. Chung S.H. Song W.J. J. Biol. Chem. 2007; 282: 34850-34857Abstract Full Text Full Text PDF PubMed Scopus (175) Google Scholar). pMX-NFATc1 WT and pMSCV-NFATc1 constitutive active (CA) mutant were also used. For DYRK knockdown experiments, oligonucleotides for small interfering RNA were generated by targeting a 21-base sequence of mouse Dyrk1a and Dyrk1b. The resulting oligonucleotide sequences (supplemental Table S2) were annealed and ligated into pSuper-retro vector (Oligoengine, Seattle, WA) using BamHI and HindIII sites. Retroviruses were packaged by transfecting plasmids into Plat-E cells. Retroviral infection of cells was performed as described previously (17.Lee Y. Hyung S.W. Jung H.J. Kim H.J. Staerk J. Constantinescu S.N. Chang E.J. Lee Z.H. Lee S.W. Kim H.H. Blood. 2008; 111: 885-893Crossref PubMed Scopus (36) Google Scholar). RAW264.7 cells were transfected with pcDNA3.1 vector or pcDNA3.1-DYRK1A and incubated with 100 ng/ml RANKL for 2 days. The cells were transfected with the reporter plasmid containing the 0.8-kb proximal region of NFATc1 promoter (20.Chuvpilo S. Jankevics E. Tyrsin D. Akimzhanov A. Moroz D. Jha M.K. Schulze-Luehrmann J. Santner-Nanan B. Feoktistova E. König T. Avots A. Schmitt E. Berberich-Siebelt F. Schimpl A. Serfling E. Immunity. 2002; 16: 881-895Abstract Full Text Full Text PDF PubMed Scopus (163) Google Scholar). At 24 h after reporter transfection, cells were lysed in GloTM lysis buffer. Luciferase activity was measured using Bright-GloTM luciferase assay system (Promega, Madison, WI) in a FLUOstar Optima luminometer (BMG Labtech GmbH, Offenburg, Germany). WT or DYRK1A TG mice (8 weeks old) were injected intraperitoneally with 25 mg/kg calcein (Sigma; dissolved in 200 μl of 2% NaHCO3, 150 mm NaCl) followed by 90 mg/kg xylenol orange (Sigma) at day 1 and day 7, respectively. Mice were sacrificed at day 10, and femurs were fixed and embedded in resin (BMP Lab, Seoul, Korea). Sections were observed under a Zeiss LSM 5 PASCAL laser-scanning microscope (Carl Zeiss Microimaging GmbH, Goettingen, Germany) with a ×40 objective (C-Apochromat/1.2 W Corr). The distance between calcein and xylenol orange deposition was calculated from five different regions of the same image in 4 slides/group using the LSM 5 image browser (version 3.1). Femurs from mice were subjected to microCT analyses using a SkyScan 1172 scanner (SkyScan, Aartselaar, Belgium; 40 kV, 250 μA, 7.9 μm pixel size). Images obtained from a 1-mm-thick distal femoral area, starting from 1 mm below the growth plate, were analyzed by the CT-analyzer program (version 1.7; SkyScan) to calculate bone volume and bone parameters. A three-dimensional reconstitution of images was performed by CT-volume software (version 1.11; SkyScan). Femurs were fixed, decalcified for 1 month in 10% EDTA, and embedded in paraffin. Sections of 5 μm thickness were prepared using Leica microtome RM2145 (Leica Microsystems, Bannockbrun, IL) and were subjected to TRAP and hematoxylin staining. Histomorphometric analysis was performed as described (21.Chang E.J. Ha J. Oerlemans F. Lee Y.J. Lee S.W. Ryu J. Kim H.J. Lee Y. Kim H.M. Choi J.Y. Kim J.Y. Shin C.S. Pak Y.K. Tanaka S. Wieringa B. Lee Z.H. Kim H.H. Nat. Med. 2008; 14: 966-972Crossref PubMed Scopus (84) Google Scholar) using the Bioquant OsteoII program (Bioquant Image Analysis Corp., Nashville, TN). Student's t test was used to determine the significance of difference between two groups. Comparison of results composed of more than two groups was done by one-way analysis of variance followed by Student-Newman-Keuls post hoc tests. Differences with p < 0.05 were regarded as significant. A detailed description of methods is provided in the supplemental material. DYRK1A expression significantly increased upon stimulation of mouse bone marrow macrophages (BMMs) with RANKL (Fig. 1A). A real-time PCR analysis revealed that RANKL significantly up-regulated Dyrk1a mRNA expression (Fig. 1B). To gain insights into the role of DYRK1A during RANKL-induced osteoclastogenesis, we down-regulated DYRK1A protein expression by introducing small interfering RNA into BMMs via retroviral infection (supplemental Fig. S1A). Osteoclast differentiation was dramatically enhanced in DYRK1A down-regulated BMMs, suggesting a negative regulatory role of DYRK1A during osteoclastogenesis (Fig. 1C). Furthermore, when DYRK1A was overexpressed in RAW264.7 macrophages (supplemental Fig. S1B), a significant decrease in osteoclastogenesis was observed (Fig. 1D). On the other hand, DYRK1B did not dramatically affect osteoclastogenesis, although its expression was significantly increased by RANKL (supplemental Fig. S2). To uncover the RANKL-dependent transcription factor(s) that might induce DYRK1A expression in osteoclasts, BMMs were infected with retroviruses to overexpress transcription factors known to be activated downstream of RANKL. Although c-Fos only slightly stimulated DYRK1A expression, both WT and constitutive active NFATc1 dramatically increased DYRK1A in the absence of RANKL (Fig. 2A), suggesting that NFATc1 might be a regulator of DYRK1A expression. Although the RANKL-dependent DYRK1A expression was suppressed by NFκB inhibitors (supplemental Fig. S3A), it was most likely due to the inhibition of NFATc1 expression because NFκB inhibitors did not reduce DYRK1A expression in the presence of constitutive active NFATc1 (supplemental Fig. S3B). It was suggested that DYRK1A might phosphorylate and thereby exclude NFAT from the nucleus (15.Gwack Y. Sharma S. Nardone J. Tanasa B. Iuga A. Srikanth S. Okamura H. Bolton D. Feske S. Hogan P.G. Rao A. Nature. 2006; 441: 646-650Crossref PubMed Scopus (317) Google Scholar, 16.Arron J.R. Winslow M.M. Polleri A. Chang C.P. Wu H. Gao X. Neilson J.R. Chen L. Heit J.J. Kim S.K. Yamasaki N. Miyakawa T. Francke U. Graef I.A. Crabtree G.R. Nature. 2006; 441: 595-600Crossref PubMed Scopus (549) Google Scholar). Indeed, there was a significant increase in the phosphorylation of NFATc1 in DYRK1A-overexpressing 293FT cells (Fig. 2B). Similar enhanced phosphorylation of NFATc1 was observed in RAW264.7 cells overexpressing DYRK1A (supplemental Fig. S3C). The accumulation of nuclear NFATc1 in response to RANKL treatment was prominently suppressed in DYRK1A-overexpressing cells (Fig. 2C). Similarly, NFATc1 in the nuclear fraction from DYRK1A-overexpressing cells did not increase upon stimulation with ionomycin (Fig. 2D). In addition, it was evident that there was little activation of NFATc1 promoter activity by RANKL in DYRK1A-overexpressing RAW264.7 cells, compared with that in control cells (Fig. 2E). DYRK1A also suppressed NFATc1-dependent IL-4 promoter activity (supplemental Fig. S3D). In accordance with the reduced NFATc1 promoter activation, RANKL-induced increase in total NFATc1 protein was significantly impaired in DYRK1A-overexpressing cells (Fig. 2F). Taken together, we suggest that DYRK1A inhibits NFATc1 activity and expression via a negative feedback regulation. The in vitro inhibition of osteoclastogenesis by DYRK1A led us to analyze the bone phenotype of DYRK1A BAC transgenic (DYRK1A TG) mice that overexpress human DYRK1A by 1.5-fold under the control of endogenous promoter to mimic the increased gene dosage of Down syndrome (6.Ahn K.J. Jeong H.K. Choi H.S. Ryoo S.R. Kim Y.J. Goo J.S. Choi S.Y. Han J.S. Ha I. Song W.J. Neurobiol. Dis. 2006; 22: 463-472Crossref PubMed Scopus (172) Google Scholar). Although we detected no emphatic skeletal anomaly in gross examination by soft x-ray (supplemental Fig. S4A), microCT analysis of femurs revealed that trabecular bone volume was markedly decreased in TG mice compared with WT (supplemental Fig. S4B). Analyses of bone parameters from microCT data further confirmed an osteoporotic bone phenotype of both male and female DYRK1A TG mice (Fig. 3A). The bone volume/tissue volume (BV/TV) in male mice was 12.7 ± 0.6% in WT and 10.1 ± 0.9% in TG femurs. Similarly, BV/TV in female mice was reduced from 12.6 ± 0.5% in WT to 10.9 ± 0.3% in TG mice. The analyses of trabecular thickness (supplemental Fig. S4C), trabecular number (supplemental Fig. S4D), and trabecular separation (supplemental Fig. S4E) indicated reduced bone mass in TG mice. However, it seemed that the extra DYRK1A did not affect cortical bone thickness of femurs (supplemental Fig. S4, F and G). The RANKL-stimulated expression of NFATc1 was significantly reduced in DYRK1A TG BMMs (Fig. 3B). We observed no significant defect in RANKL-dependent mitogen-activated kinase activation (supplemental Fig. S5A), indicating that the signaling pathways known to regulate RANKL-dependent NFATc1 expression in BMMs were not affected. Both proliferation (supplemental Fig. S5B) and RANKL-induced osteoclastogenesis (Fig. 3C and supplemental Fig. S5C) were significantly impaired in DYRK1A TG BMMs. A real-time PCR analysis revealed significant reduction of osteoclast differentiation markers Acp5, Calcr, and, to a lesser extent, Ctsk in TG BMMs following RANKL stimulation (Fig. 3D). In agreement with the reduced osteoclast differentiation, the resorption activity of TG osteoclasts was significantly lower than that of WT osteoclasts (data not shown). However, when DYRK1A TG BMMs were forced to express WT or constitutive active NFATc1, defective osteoclastogenesis was restored (Fig. 3E). Since the impaired osteoclastogenesis contradicted the reduced bone mass in DYRK1A TG mice, we next investigated the function of osteoblasts in TG mice. Stimulation of osteoblast differentiation in mouse calvarial cells with β-glycerophosphate and ascorbic acid significantly induced DYRK1A expression (Fig. 4A). Interestingly, the induction of DYRK1A paralleled NFATc1 expression. Overexpression of NFATc1 in calvarial cells induced DYRK1A expression (Fig. 4B), suggesting that DYRK1A might be under the regulation of negative feedback loop as in osteoclasts. A markedly reduced NFATc1 induction by BMP-2 was observed in TG osteoblasts (Fig. 4C), whereas extra DYRK1A did not affect BMP-2-dependent Smad phosphorylation (supplemental Fig. S6A). Treatment of osteoblasts with BMP-2 increased nuclear NFATc1 in WT cells but not in DYRK1A TG cells (Fig. 4D). In addition, proliferation (supplemental Fig. S6B) and differentiation (Fig. 4E) of calvarial osteoblasts were significantly impaired in DYRK1A TG mice. The inhibition of NFATc1 by a calcineurin inhibitor cyclosporine A resulted in a significant attenuation of osteoblast differentiation, suggesting a role for NFATc1 in osteoblasts (supplemental Fig. S6C). A real-time PCR analysis revealed that the mRNA expression of osteoblast differentiation markers, including Bglap1, Alpl, and Col1a1, was significantly reduced in DYRK1A TG osteoblasts (Fig. 4F). Interestingly, however, the expression of Tnfsf11 was consistently higher in TG than in WT osteoblasts. DYRK1A TG osteoblasts formed less mineralized nodules (Fig. 4G). In vivo bone formation, measured by the distance between the two fluorescence labels after sequential labeling of femurs with calcein and xylenol orange, was visibly impaired in TG mice (Fig. 4H). Accordingly, mineral apposition rate was significantly lower in TG mice (supplemental Fig. S6D). However, presumably due to the compensatory effect of increased RANKL (encoded by Tnfsf11) expression in TG osteoblasts, impaired TG osteoblast function by extra DYRK1A did not affect osteoclastogenesis in an osteoblast-BMM coculture system (Fig. 4I and supplemental Fig. S6E). Taken together, DYRK1A plays a negative regulatory role during normal osteoblast differentiation. In DYRK1A TG mice, impaired osteoblast function seemingly overrode impeded osteoclast function, resulting in the reduced bone mass. To examine the effect of extra DYRK1A on bone resorption in TG mice, we adopted an LPS challenge and ovariectomy model that emulates inflammation- and hormone deprivation-induced bone loss. A three-dimensional visualization of distal femoral area showed massive loss of trabecular bone following LPS treatment in WT mice (Fig. 5A). On the other hand, no further significant loss of trabecular bone was observed in DYRK1A TG mice challenged with LPS. This was clearly demonstrated when bone volume was analyzed from microCT data (Fig. 5B). The BV/TV was 9.2 ± 0.2% for the PBS-treated group and 7.3 ± 0.2% for the LPS-treated group in WT mice. However, there was no statistical difference in the bone volume of femurs between PBS- and LPS-challenged TG mice (8.1 ± 0.2% for the PBS-treated group and 8.0 ± 0.2% for the LPS-treated group). Analyses of trabecular thickness and trabecular number also revealed that LPS did not induce trabecular bone loss in DYRK1A TG mice (supplemental Fig. S7, A and B). Consistent with the microCT results, histological analyses revealed significant loss of trabecular bone accompanied by increased TRAP activity in femoral sections from LPS-treated WT mice compared with PBS-treated groups (Fig. 5C). On the other hand, no such bone loss and increase of TRAP-positive osteoclasts were observed in DYRK1A TG mice upon LPS treatment. Assessment of the osteoclast and osteoblast numbers also indicated that DYRK1A TG mice were protected from LPS effects (Fig. 5D and supplemental Fig. S7C). A three-dimensional reconstitution of microCT images (supplemental Fig. S8A) and an analysis of microCT data (Fig. 5E) from ovariectomized mice also revealed that ovariectomy reduced bone volume by more than 30% in WT mice. The BV/TV was 15.6 ± 0.5% in sham-operated and 10.4 ± 0.6% in ovariectomized WT mice. However, the femoral bone volume of DYRK1A TG mice was not affected by ovariectomy (13.5 ± 0.1% in sham-operated and 13.4 ± 0.4% in ovariectomized mice) (Fig. 5E). Analyses of trabecular thickness (supplemental Fig. S8B) and trabecular number (supplemental Fig. S8C) also indicated that ovariectomy resulted in a significant trabecular bone loss only in WT mice. Histological analyses were consistent with the microCT results, showing no increase of TRAP-positive osteoclasts and bone loss in DYRK1A TG mice following ovariectomy (supplemental Fig. S8D). The number of osteoblasts in sham-operated and ovariectomized TG mice was significantly smaller than that of corresponding WT mice (supplemental Fig. S8E). Although osteoclast number per bone perimeter dramatically increased following ovariectomy in WT mice, the increase was insignificant in TG mice (Fig. 5F). Taken together, these results suggest that DYRK1A TG mice are apparently resistant to LPS- and ovariectomy-induced bone loss. In the present report, we investigated the role of DYRK1A in bone homeostasis. Intriguingly, in an effort to delineate signaling pathways responsible for the induction of DYRK1A, we discovered that NFATc1 stimulated the expression of DYRK1A in both osteoclast precursors and osteoblasts. Since NFATc1 activity and expression were inhibited by DYRK1A, it is likely that there is a negative feedback mechanism. In this hypothesis, increased NFATc1 upon pro-osteoclastogenic signals in osteoclast precursors induces DYRK1A expression, which in turn attenuates NFATc1 activity and expression, thereby limiting excessive osteoclastogenesis. DYRK1A inhibited NFATc1 nuclear localization and activity via phosphorylation. Importantly, DYRK1A also reduced NFATc1 promoter activity, suggesting a crucial role for DYRK1A in the regulation of NFATc1 autoamplification process (22.Asagiri M. Sato K. Usami T. Ochi S. Nishina H. Yoshida H. Morita I. Wagner E.F. Mak T.W. Serfling E. Takayanagi H. J. Exp. Med. 2005; 202: 1261-1269Crossref PubMed Scopus (670) Google Scholar). The schematic diagram in Fig. 6, A and B, depicted this DYRK1A-dependent negative feedback regulation of osteoclastogenesis. Similarly, bone formation-inducing signals, such as BMP-2, induce NFATc1 expression in osteoblasts. Enhanced DYRK1A by NFATc1 turns down NFATc1 signaling to prevent uncontrolled bone formation. Thus, the DYRK1A-NFATc1 negative feedback loop might serve as a mechanism to maintain bone homeostasis and to prevent pathologic bone destruction or bone formation. The role of DYRK1A in Down syndrome has been of particular interest due to its location on human chromosome 21q22.2 region, denoted as the “Down syndrome critical region,” which is believed to contain crucial genes for Down syndrome pathogenesis (23.Delabar J.M. Theophile D. Rahmani Z. Chettouh Z. Blouin J.L. Prieur M. Noel B. Sinet P.M. Eur. J. Hum. Genet. 1993; 1: 114-124Crossref PubMed Scopus (395) Google Scholar). The BAC DYRK1A TG mice used in this study have benefits as a clinically relevant model because these mice carry only one copy of human DYRK1A under the control of the endogenous promoter region (see the supplemental material for detailed discussion). As a result, these mice exhibited ∼1.5-fold overexpression of DYRK1A protein, providing an optimal model to study the role of DYRK1A in Down syndrome pathogenesis (6.Ahn K.J. Jeong H.K. Choi H.S. Ryoo S.R. Kim Y.J. Goo J.S. Choi S.Y. Han J.S. Ha I. Song W.J. Neurobiol. Dis. 2006; 22: 463-472Crossref PubMed Scopus (172) Google Scholar, 19.Ryoo S.R. Jeong H.K. Radnaabazar C. Yoo J.J. Cho H.J. Lee H.W. Kim I.S. Cheon Y.H. Ahn Y.S. Chung S.H. Song W.J. J. Biol. Chem. 2007; 282: 34850-34857Abstract Full Text Full Text PDF PubMed Scopus (175) Google Scholar, 24.Ryoo S.R. Cho H.J. Lee H.W. Jeong H.K. Radnaabazar C. Kim Y.S. Kim M.J. Son M.Y. Seo H. Chung S.H. Song W.J. J. Neurochem. 2008; 104: 1333-1344Crossref PubMed Scopus (149) Google Scholar). Several groups have reported that the bone mineral density in Down syndrome patients is significantly lower than that in normal population. Importantly, the reduced bone density was observed in both males and females even in young age groups (25.Center J. Beange H. McElduff A. Am. J. Ment. Retard. 1998; 103: 19-28Crossref PubMed Scopus (150) Google Scholar, 26.Angelopoulou N. Matziari C. Tsimaras V. Sakadamis A. Souftas V. Mandroukas K. Calcif. Tissue Int. 2000; 66: 176-180Crossref PubMed Scopus (100) Google Scholar, 27.Guijarro M. Valero C. Paule B. Gonzalez-Macias J. Riancho J.A. J. Intellect. Disabil. Res. 2008; 52: 182-189Crossref PubMed Scopus (69) Google Scholar, 28.Sakadamis A. Angelopoulou N. Matziari C. Papameletiou V. Souftas V. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002; 100: 208-212Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar, 29.Baptista F. Varela A. Sardinha L.B. Osteoporos. Int. 2005; 16: 380-388Crossref PubMed Scopus (95) Google Scholar). This was in sharp contrast with the prevalence of osteoporosis in elderly women in normal population. However, the etiology of osteoporosis among Down syndrome patients has remained ambiguous and under debate until the present. The current explanations range from the existence of an additional gene(s) on extra chromosome 21 to malnutrition and sedentary life style among Down syndrome patients. Here we showed for the first time that the 1.5-fold overdose of DYRK1A alone was sufficient to induce significant reduction in bone volume (21% in male mice and 13% in female mice) (Fig. 3A), reminiscent of the Down syndrome-associated osteoporosis. Inhibition of NFATc1 activity by additional DYRK1A resulted in a compromised osteoblast proliferation, differentiation, and mineralization, supporting a suggested role of NFATc1 in osteoblastogenesis (30.Koga T. Matsui Y. Asagiri M. Kodama T. de Crombrugghe B. Nakashima K. Takayanagi H. Nat. Med. 2005; 11: 880-885Crossref PubMed Scopus (390) Google Scholar, 31.Winslow M.M. Pan M. Starbuck M. Gallo E.M. Deng L. Karsenty G. Crabtree G.R. Dev. Cell. 2006; 10: 771-782Abstract Full Text Full Text PDF PubMed Scopus (275) Google Scholar). At the same time, the proliferation, differentiation, and function of osteoclasts were also diminished in DYRK1A TG mice. From these results, we suggest that extra DYRK1A in DYRK1A TG mice and Down syndrome patients sets a new equilibrium for NFATc1 signaling in bone homeostasis, reducing bone turnover (Fig. 6C). In concert with this hypothesis, we observed consistently lower numbers of osteoblasts and osteoclasts in bones from DYRK1A TG mice in accordance with the reported “adynamic” bone phenotype in Down syndrome patients (32.Grimwood J.S. Kumar A. Bickerstaff D.R. Suvarna S.K. Histopathology. 2000; 36: 279-280Crossref PubMed Scopus (14) Google Scholar). Notably, the Down syndrome critical region also contains DSCR1, which encodes a calcineurin inhibitor. As a result, the phosphorylated state of NFATc1 might be further sustained by inhibition of calcineurin (16.Arron J.R. Winslow M.M. Polleri A. Chang C.P. Wu H. Gao X. Neilson J.R. Chen L. Heit J.J. Kim S.K. Yamasaki N. Miyakawa T. Francke U. Graef I.A. Crabtree G.R. Nature. 2006; 441: 595-600Crossref PubMed Scopus (549) Google Scholar), possibly magnifying the effect of DYRK1A on NFATc1 activity and bone homeostasis in Down syndrome. Historically, it was of great interest to search for a gene(s) on human chromosome 21 that is responsible for specific Down syndrome pathogenesis. In this context, the possible involvement of DYRK1A in Down syndrome skeletal anomalies in addition to the osteoporotic bone phenotype might be worthy of pursuit. Notably, however, we could not observe significant gross malformations in the skeletal system, such as a craniofacial defect in DYRK1A TG mice, in contrast to Down syndrome patients and trisomy-16 mice (33.Richtsmeier J.T. Baxter L.L. Reeves R.H. Dev. Dyn. 2000; 217: 137-145Crossref PubMed Scopus (193) Google Scholar, 34.Richtsmeier J.T. Zumwalt A. Carlson E.J. Epstein C.J. Reeves R.H. Am. J. Med. Genet. 2002; 107: 317-324Crossref PubMed Scopus (102) Google Scholar). Indeed, mice trisomic only for the Down syndrome critical region did not show a distinctive facial phenotype (35.Olson L.E. Richtsmeier J.T. Leszl J. Reeves R.H. Science. 2004; 306: 687-690Crossref PubMed Scopus (248) Google Scholar), suggesting that genes in this region may not be involved. Alternatively, mice overexpressing Ets2 that is located outside of the Down syndrome critical region had defects in cranial and cervical skeleton formation (36.Sumarsono S.H. Wilson T.J. Tymms M.J. Venter D.J. Corrick C.M. Kola R. Lahoud M.H. Papas T.S. Seth A. Kola I. Nature. 1996; 379: 534-537Crossref PubMed Scopus (181) Google Scholar). However NFATc1, a substrate of DYRK1A, has been linked to craniofacial anomalies in mice. Recent reports observed craniofacial malformations in Nfatc1nuc mice that express the constitutive active form of NFATc1 (31.Winslow M.M. Pan M. Starbuck M. Gallo E.M. Deng L. Karsenty G. Crabtree G.R. Dev. Cell. 2006; 10: 771-782Abstract Full Text Full Text PDF PubMed Scopus (275) Google Scholar), viable Nfatc1−/− mice (31.Winslow M.M. Pan M. Starbuck M. Gallo E.M. Deng L. Karsenty G. Crabtree G.R. Dev. Cell. 2006; 10: 771-782Abstract Full Text Full Text PDF PubMed Scopus (275) Google Scholar), and Nfatc2−/−Nfatc4−/− double knock-out mice (16.Arron J.R. Winslow M.M. Polleri A. Chang C.P. Wu H. Gao X. Neilson J.R. Chen L. Heit J.J. Kim S.K. Yamasaki N. Miyakawa T. Francke U. Graef I.A. Crabtree G.R. Nature. 2006; 441: 595-600Crossref PubMed Scopus (549) Google Scholar), suggesting possible gene dosage-dependent mechanisms for NFATc proteins in the regulation of skeletal development. Taken together, although it is believed that the regulation of NFATc1 by DYRK1A alone is sufficient to control bone homeostasis, skeletal development might be governed by additional mechanism(s). Further studies are required to clearly define the mechanism of NFATc protein regulation in skeletal anomalies observed in Down syndrome. Notwithstanding the deleterious effect on bone mass in unchallenged DYRK1A TG mice, extra DYRK1A was beneficial in protecting these mice from experimental bone loss induced by inflammation or hormone deprivation. As summarized in Fig. 6C, bone destruction by LPS or ovariectomy was prevented because the negative-regulation of NFATc1 reduced osteoclastogenesis in DYRK1A TG mice. In efforts to develop a strategy to prevent osteoporosis, NFATc1 has been suggested as a target molecule due to its role in osteoclastogenesis (22.Asagiri M. Sato K. Usami T. Ochi S. Nishina H. Yoshida H. Morita I. Wagner E.F. Mak T.W. Serfling E. Takayanagi H. J. Exp. Med. 2005; 202: 1261-1269Crossref PubMed Scopus (670) Google Scholar, 37.Takayanagi H. Kim S. Koga T. Nishina H. Isshiki M. Yoshida H. Saiura A. Isobe M. Yokochi T. Inoue J. Wagner E.F. Mak T.W. Kodama T. Taniguchi T. Dev. Cell. 2002; 3: 889-901Abstract Full Text Full Text PDF PubMed Scopus (1986) Google Scholar). We suggest that targeting DYRK1A instead of directly modulating NFATc1 might provide an efficient strategy for treating bone-destructive diseases, because only a 50% increase in the DYRK1A protein level was enough to completely prevent bone loss in animal models. To summarize, we have discovered a negative feedback mechanism for DYRK1A-NFATc1 regulation, which affects bone homeostasis. Our results provide an insight into the novel role for DYRK1A in the regulation of bone mass in normal and pathologic conditions, including Down syndrome-associated osteoporosis, as well as prospects for therapeutic applications for bone-destructive diseases. We thank Min-Su Jung for technical support in animal experiments. Download .zip (3.42 MB) Help with zip files" @default.
• W2059617293 created "2016-06-24" @default.
• W2059617293 creator A5017935217 @default.
• W2059617293 creator A5020722899 @default.
• W2059617293 creator A5030321855 @default.
• W2059617293 creator A5039037935 @default.
• W2059617293 creator A5045030835 @default.
• W2059617293 creator A5058368777 @default.
• W2059617293 creator A5071099098 @default.
• W2059617293 date "2009-11-01" @default.
• W2059617293 modified "2023-10-01" @default.
• W2059617293 title "Negative Feedback Inhibition of NFATc1 by DYRK1A Regulates Bone Homeostasis" @default.
• W2059617293 cites W1493924061 @default.
• W2059617293 cites W1860217789 @default.
• W2059617293 cites W1967502057 @default.
• W2059617293 cites W1971955679 @default.
• W2059617293 cites W1974025476 @default.
• W2059617293 cites W1979678145 @default.
• W2059617293 cites W1992995639 @default.
• W2059617293 cites W1993192620 @default.
• W2059617293 cites W1995261845 @default.
• W2059617293 cites W1997381668 @default.
• W2059617293 cites W2014157276 @default.
• W2059617293 cites W2014225480 @default.
• W2059617293 cites W2017372504 @default.
• W2059617293 cites W2017884068 @default.
• W2059617293 cites W2037155680 @default.
• W2059617293 cites W2038769797 @default.
• W2059617293 cites W2040150222 @default.
• W2059617293 cites W2042916026 @default.
• W2059617293 cites W2058968970 @default.
• W2059617293 cites W2064346787 @default.
• W2059617293 cites W2079491737 @default.
• W2059617293 cites W2082557543 @default.
• W2059617293 cites W2084214367 @default.
• W2059617293 cites W2084963741 @default.
• W2059617293 cites W2088136720 @default.
• W2059617293 cites W2090850273 @default.
• W2059617293 cites W2092247599 @default.
• W2059617293 cites W2093252878 @default.
• W2059617293 cites W2099999081 @default.
• W2059617293 cites W2110646442 @default.
• W2059617293 cites W2116247013 @default.
• W2059617293 cites W2122518329 @default.
• W2059617293 cites W2129736783 @default.
• W2059617293 cites W2132408993 @default.
• W2059617293 cites W2147154230 @default.
• W2059617293 cites W2170384111 @default.
• W2059617293 doi "https://doi.org/10.1074/jbc.m109.042234" @default.
• W2059617293 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2785177" @default.
• W2059617293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19801542" @default.
• W2059617293 hasPublicationYear "2009" @default.
• W2059617293 type Work @default.
• W2059617293 sameAs 2059617293 @default.
• W2059617293 citedByCount "60" @default.
• W2059617293 countsByYear W20596172932012 @default.
• W2059617293 countsByYear W20596172932013 @default.
• W2059617293 countsByYear W20596172932014 @default.
• W2059617293 countsByYear W20596172932015 @default.
• W2059617293 countsByYear W20596172932016 @default.
• W2059617293 countsByYear W20596172932017 @default.
• W2059617293 countsByYear W20596172932018 @default.
• W2059617293 countsByYear W20596172932019 @default.
• W2059617293 countsByYear W20596172932020 @default.
• W2059617293 countsByYear W20596172932021 @default.
• W2059617293 countsByYear W20596172932022 @default.
• W2059617293 countsByYear W20596172932023 @default.
• W2059617293 crossrefType "journal-article" @default.
• W2059617293 hasAuthorship W2059617293A5017935217 @default.
• W2059617293 hasAuthorship W2059617293A5020722899 @default.
• W2059617293 hasAuthorship W2059617293A5030321855 @default.
• W2059617293 hasAuthorship W2059617293A5039037935 @default.
• W2059617293 hasAuthorship W2059617293A5045030835 @default.
• W2059617293 hasAuthorship W2059617293A5058368777 @default.
• W2059617293 hasAuthorship W2059617293A5071099098 @default.
• W2059617293 hasBestOaLocation W20596172931 @default.
• W2059617293 hasConcept C11960822 @default.
• W2059617293 hasConcept C126322002 @default.
• W2059617293 hasConcept C134018914 @default.
• W2059617293 hasConcept C185592680 @default.
• W2059617293 hasConcept C2777736865 @default.
• W2059617293 hasConcept C63645605 @default.
• W2059617293 hasConcept C71924100 @default.
• W2059617293 hasConcept C86803240 @default.
• W2059617293 hasConcept C95444343 @default.
• W2059617293 hasConceptScore W2059617293C11960822 @default.
• W2059617293 hasConceptScore W2059617293C126322002 @default.
• W2059617293 hasConceptScore W2059617293C134018914 @default.
• W2059617293 hasConceptScore W2059617293C185592680 @default.
• W2059617293 hasConceptScore W2059617293C2777736865 @default.
• W2059617293 hasConceptScore W2059617293C63645605 @default.
• W2059617293 hasConceptScore W2059617293C71924100 @default.
• W2059617293 hasConceptScore W2059617293C86803240 @default.
• W2059617293 hasConceptScore W2059617293C95444343 @default.
• W2059617293 hasIssue "48" @default.
• W2059617293 hasLocation W20596172931 @default.
• W2059617293 hasLocation W20596172932 @default.
• W2059617293 hasLocation W20596172933 @default.

• next